The coronavirus pandemic has caused major disruptions to commercial life science companies conducting clinical trials. To effectively plan the continuation of trials during this period, companies must first consider the Food and Drug Administration (FDA) and European Medicines Agency (EMA) COVID-19 guidance documents and consider what resources are available to effectively manage patient visits during this pandemic in order to conform to the relevant regulatory requirements.
Listen to Baker Tilly’s on-demand webinar for an informative discussion that will address:
For more information on this topic, or to learn how Baker Tilly's Value Architects™ can help, contact our team.